# Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

> **NCT01627132** · PHASE2 · UNKNOWN · sponsor: **Shimousa Hematology Study Group** · enrollment: 50 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT01627132
- **Lead sponsor:** Shimousa Hematology Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-02
- **Primary completion:** 2017-02
- **Final completion:** 2019-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2012-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01627132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01627132, "Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01627132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*